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Abstract The product of gas6 (Gas6) is a growth factor with 
high level of similarity to protein S and was identified as the 
ligand for Axl family of tyrosine kinase receptors. Gas6 contains 
an N-terminal γ-carboxylated domain (Gla), four epidermal 
growth factor like domains and a large C-terminal D region. An 
alternative Gas6 spliced form (Gas6SV) having an additional 43 
amino acids between fourth EFG like and D domain was 
characterised. Here we show data indicating that GasóSV is 
specifically cleaved within the inserted sequence, thereby splitting 
the D domain from the remaining part of the protein. The 
resulting two proteolytic products of 36 kDa and 50 kDa were 
separated and the 50 kDa fragment corresponding to region D 
was shown to be responsible for Axl receptor activation. 
Furthermore a deletion mutant of Gas6 containing only the D 
domain was shown to similarly activate Axl receptor phospho-
rylation unequivocally demonstrating that D domain can act as a 
signalling molecule. The possible roles of the proteolytic 
processing of GasóSV in the regulation of growth factor 
availability are discussed. 
© 1997 Federation of European Biochemical Societies. 
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These receptors are expressed in a number of tissues. Rel-
atively high levels of expression have been detected for Axl in 
heart and skeletal muscle [8], for Mer in human testis, ovary, 
prostate, lung, kidney [10], and for Rse in the adult brain 
[11,12]. 
We have previously reported that Gas6 is able to induce cell 
cycle re-entry of serum starved NIH3T3 cells and to efficiently 
prevent cell death by apoptosis induced by complete serum 
removal [13]. More recently we have demonstrated that Gas6 
signalling requires a PI3K activated pathway for both mito-
genic and anti-apoptotic effect [14]. An alternative splice form 
of gas6 has been described (accompanying manuscript) con-
taining an additional 43 amino acid sequence between fourth 
EGF and C-terminal D domain. Here we report on the anal-
ysis of the product of such alternative gas6 spliced form 
(GasóSV), which is proteolytically cleaved within the inserted 
peptide. Biochemical separation of the two proteolytic prod-
ucts (36 kDa and 50 kDa) together with the analysis of Gas6 
deletion mutants allowed us to show that the 50 kDa C-ter-
minal region of GasóSV is responsible for Axl activation. This 
alternative splicing event may therefore uncover a novel form 
of regulation for the growth factor availability. 
1. Introduction 
Gas6 was initially isolated as a product of a gene whose 
expression is increased at growth arrest [1]. The protein en-
coded by gasó (Gasó) is a 75 kDa protein highly related to 
protein S (PS), a negative regulator of blood coagulation and 
can similarly be divided into defined domains [2]. The Gla 
domain is rich in γ-carboxyglutamic acid (Gla) and is involved 
in the Ca2+ dependent binding of PS to membrane phospho-
lipids [3]. The loop region contains a thrombin cleavage site in 
PS which is absent in Gas6 and is followed by four EGF like 
repeats. The C-terminal region of Gas6 is homologous to 
steroid binding globulin protein (SHBG), and contains tan-
dem globular domains [2]. 
Human Gas6 was shown to act as the ligand for three 
members of the Axl family of tyrosine kinases: Axl, Rse 
and Mer [4-7]. The extracellular domains of the Axl/Rse/ 
Mer include two immunoglobulin like repeats followed by 
two fibronectin type III repeats reminiscent of the extracellu-
lar region of neural cell adhesion molecules [8]. Consistently 
murine Axl homologue, Ark, has been reported to be involved 
in cell to cell interaction through the ability of the extracel-
lular portion to undergo homophylic binding [9]. 
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2. Materials and methods 
2.1. Plasmids, DNA deletion and swapping strategy 
Human gasó and gas6SV cDNA were cloned in pGDSV7 eukary-
otic expression vector under SV40 virus promoter for constitutive 
expression and were described elsewhere (and accompanying paper). 
Gas6 deletion mutants (AC, AD) were obtained as follows: for AC 
deletion, pBluescript gas6 [2], (Stratagene), was digested with ApaLI 
and MscI and the resulting vector containing gas6AC was gel puri-
fied, blunted with DNA polymerase Klenow fragment (Pharmacia) 
and religated; for AD deletion, pGDSV7gas6 was digested with 
EcoRI and MscI and cloned into pCITE-2b (Novagene, Madison, 
WI) for reconstitution of the stop codon. Gasó D domain substitution 
(ABC gas6-D PS swapping) was obtained by splicing overlap exten-
sion using pBluescript-gíiió and pBluescript-PS' (kindly provided by 
B. Dahlback, University of Lund, Sweden) as template in PCR. All 
Gas6 derivatives were inserted into pGDSV7 vector [15] for constitu-
tive expression as EcoRI-Xbal fragments. gas6 was cloned into epi-
somal mammalian vector pCEP4 (Invitrogen) for constitutive expres-
sion in 293 cells. Restriction enzymes were from New England Biolabs 
and Promega while Taq polymerase was from Perkin-Elmer. 
2.2. Cell culture and transfection of COS-7 cells 
COS-7, 293 and A172 cells were grown routinely in Dulbecco's 
modified Eagle medium (DMEM) supplemented with 10% foetal 
calf serum (FCS), penicillin (100 U/ml), and streptomycin (100 μg/ 
ml). COS-7 cells were transfected with the DEAE dextran method as 
described in [13]. Briefly, subconfluent cell cultures growing in 35 mm 
petri dish were washed twice with PBS and then overlaid with 400 μΐ 
of DEAE dextran (50 μg/ml) (Pharmacia) in serum free DMEM pre-
mixed with 2 μg of the pGDSV-7gas6 or pGDSV-7gas6SV cDNA. 
0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
P / /S0014-5793 (9 7)01093-4 
60 S. Goruppi et al.lFEBS Letters 415 (1997) 59-63 
Similar amounts were used for each gas6 mutant deletion derivative. 
A separate petri dish was mock transfected and used as control. After 
30 min at 37°C, 2 ml of DMEM 10% FCS supplemented with 100 μΜ 
chloroquine (Boehringer Mannheim) were added and cells incubated 
for further 3-5 h. Within 24 h after transfection, the medium was 
changed with DMEM 0.5% FCS, 5 μg/ml Vit Kl (Konakion, Roche). 
Two days later cell supernatants were centrifuged at 2500 Xg and 
stored at —80°C for subsequent analysis. 293 cells were transfected 
using a CaPC>4 protocol as previously described [14]. 
2.3. Antibody production 
Production and characterisation of the affinity purified antibody 
recognising Gas6 D region and Gas6 amino terminal A region were 
described elsewhere [2,4]. To produce an antibody specific for the 
insertion peptide of Gas6SV, a peptide spanning amino acids from 
296 to 329 within the inserted sequence (GRGAQGSRSE-
GHIPDRRGPRPWQC) was synthesised according to the Fmoc solid 
phase peptide synthesis methods [16] and crosslinked to haemocyanin 
(Boehringer Mannheim) using glutaraldehyde (Sigma). The rabbit was 
first injected with 200 μg of the coupled peptide diluted in Freund's 
complete adjuvant (Sigma) and subsequently injected with the same 
amount of conjugated peptide in incomplete Freund's adjuvant every 
20 days. 5 mg of the same peptide used for immunisation were co-
valently coupled to SulfoLink resin (Pierce) according to the manu-
facturer's instructions and the resulting column was used for affinity 
purification of the specific antibodies. 
2.4. Western blotting 
Equal amounts of total proteins, as assessed by Bradford analysis, 
from mock transfected, gas6, gas6SV or gas6 mutant deletion trans-
fected COS-7 cell supernatants were separated by 15% SDS-PAGE 
and blotted on a 0.25 μ nitrocellulose membrane (S and S). The nitro-
cellulose sheets were saturated for 2 h in 5% non-fat dry milk, 200 
mM NaCl, 50 mM Tris pH 7.5 and 0.02% Tween 20, and separately 
incubated overnight with the specific antibody. After this time bound 
antibodies were revealed using a goat anti-rabbit horseradish per-
oxidase conjugated antibody and ECL solutions (Amersham, UK). 
Analysis of Axl receptor activation with antiphosphotyrosine antibod-
ies PY20 (Transduction laboratories) was performed on COS-7 cells 
serum starved (DMEM 0.5% FCS) for 24 h as previously described 
[13]. 
2.5. Protein purification and activity determination 
293 cell supernatant from cells transfected with a gas6SV-pCEP4 
(Invitrogen) was adjusted to 2 mM EDTA and loaded onto a Q-
Sepharose column equilibrated with 150 mM NaCl, 2 mM EDTA, 
1 mM Benzamidine (Sigma), 20 mM Tris pH 7.4. The flow through 
material containing the D region was reserved for further analysis. 
The material which bound to the column was eluted first with 10 mM 
CaCl2 and then with a gradient of NaCl (from 150 mM to 500 mM). 
Fractions were analysed by Western blotting for the presence of the 
full length Gas6SV or the N-terminal 36 kDa region. Appropriate 
fractions were buffer exchanged by repeated centrifugations on Cen-
tricon concentrators (Amicon) and subsequent dilution with DMEM. 
The activity of these fractions was determined by receptor phospho-
rylation assay [4]. 
3. Results and discussion 
F r o m the original screening for the isolation of human gas6 
homologue, we isolated a gasó alternative spliced form 
(gasóSV) containing an additional open reading frame coding 
for 43 amino acids between the fourth E G F domain and the 
C-terminal D domain. In order to produce GasóSV recombi-
nant protein, Cos cells were transfected with the gasóSV 
c D N A and the production of GasóSV in the supernatant 
was assayed by Western blot. In parallel experiments Cos cells 
were mock or transfected with gas6 and used as control. 
Western blot analysis was carried out with three different anti-
bodies recognising the N-terminus (A region), the C-terminus 
(D region) or the specific peptide sequence within the insertion 
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Fig. 1. GasöSV is proteolytically cleaved. A: GasóSV protein organisation after Manfioletti et al., 1993. The white box indicates GasóSV γ-car-
boxylated domain A which is followed by the short linker region B (black box) and the four EGF repeats containing domain C (shaded box). 
The black box indicates the 43 amino acid sequence of the GasóSV insertion, while the spotted box represent the large C-terminal D domain. 
The bars under GasóSV regions indicate the localisation of amino acid sequences used for antibodies production. B: Western blot analysis of 
mock, gas6 and gasóSV transfected COS-7 cells as assayed with antibodies recognising separate GasóSV regions. Equal amounts of total pro-
teins, as assessed by Bradford analysis, from the supernatant of mock transfected, gas6 or gasóSV transfected COS-7 cells were separated by 
15% SDS-PAGE. Nitrocellulose membranes were separately incubated with antibodies specific for N-terminal region (Ab anti-A), or insertion 
(Ab anti-Ins) or C-terminal region (Ab anti-D). 
S. Goruppi et al.lFEBS Letters 415 (1997) 59-63 61 
Fig. 2. Biochemical fractionation of the processed Gas6SV products 
and identification of the Axl activation domain. A: Gas6SV protein 
fractionation. 293 cell supernatant from cells transfected with a 
gas6SV-pCEP4 was loaded onto a Q-Sepharose column (CM). The 
flow through contained only the C-terminal D region of Gas6SV 
(C). The bound Gas6SV proteins were eluted first with 10 mM 
CaCl2 (N) and subsequently with a NaCl gradient (FL+N). The 
fractions were separated on SDS-PAGE gel and analysed by West-
ern blotting for the presence of the full length Gas6SV or the N-ter-
minal 36 kDa region. B: Analysis of Gas6SV purified fractions for 
Axl receptor autophosphorylation. Gas6SV fractions purified as de-
scribed were tested in receptor autophosphorylation assay [4]. West-
ern blot analysis with antiphosphotyrosine antibodies of Axl recep-
tors immunoprecipitated from A172 cells before (NA) and after 
stimulation either with the 293 conditioned medium (CM), or the 
flow through containing the D domain (C), or the proteins eluted 
with the NaCl gradient (FL+N) and CaCl2 addition (N). 
(Ins). As expected gas6SV transient expression yielded a prod-
uct which was slightly larger than the Gas6 protein (Gas6 as 
compared to GasoSV, Fig. 1, panel A and B). Interestingly, 
the majority of GasoSV protein in the supernatant was 
cleaved into a 36 kDa product (N-terminal region) and a 50 
kDa product (C-terminal region). Such proteolytic processing 
most likely took place in the extracellular compartment, since 
only the full length protein could be detected in the cellular 
fraction (not shown). The split products were also found in 
the supernatant from 293 cells and murine NIH3T3 fibro-
blasts similarly transfected with gas6SV thus suggesting that 
processing of GasoSV involves a protease expressed by differ-
ent cell types. Moreover, since anti-Ins antibodies recognise 
the 50 kDa form in Western blot (Fig. 1, panel B), the site 
recognised by such protease may be contained in the C-termi-
nal region of the inserted peptide sequence. 
Biochemical separation of the two proteolytic products 
from conditioned medium of stable transfected 293 cells 
(CM) was performed by Q Sepharose chromatography, based 
on the presence of several negative charges in the Gla domain. 
Different fractions containing respectively the C-terminal 50 
kDa product (C), the N-terminal 36 kDa product (N) and a 
mixture of full length and the 36 kDa (N+FL) (Fig. 2, panel 
A) were obtained. The purified fractions as well as the starting 
material from 293 supernatants were tested for their ability to 
stimulate Axl phosphorylation in A172 cells as previously 
reported [4]. As shown in Fig. 2, panel B, stimulation of 
Axl activity, detected as increased tyrosine phosphorylation, 
was associated with the fractions containing the 50 kDa C-
terminal D domain alone or both p50 and full length Gas6SV. 
No Axl phosphorylation was detected when the N-terminal 
portion of the protein containing the EGF repeats was tested 
(Fig. 2, panel B). In addition, activation of Axl receptor ty-
rosine kinase activity by the purified C-terminal region was 
similar to that obtained with the conditioned medium contain-
ing the full length Gas6SV, further suggesting that Gas6 D 
domain is responsible for Axl stimulation. Thus, the EGF 
repeats are apparently not essential for receptor activation 
and may therefore be involved in additional Gas6 (and 
Gas6SV) interactions. 
In order to confirm the ability of the D domain to activate 
Axl receptor, we produced Gas6 mutant deletions lacking the 
D domain (Gas6AD) or lacking the region containing the 
four EGF (Gas6AC). An additional construct was obtained 
by replacing the Gas6 D region with the corresponding D 
region of protein S (Gas6-DPS) [5]. 
Cos cells were transfected with gasó, gasóSV, gasóAC, 
gasóAD and gas6-DPS as described above and the recombi-
nant proteins were allowed to accumulate in the supernatant 
for 48 h. Equal amounts of cell supernatant were separated by 
15% SDS-PAGE, blotted on membranes and revealed using 
antibodies recognising the amino terminus of Gas6. Cos cells 
were also mock transfected and used as control. Gas6, 
Gas6SV and all the mutant deletion proteins were secreted 
and were found in the supernatant of transfected cells (Fig. 
3, panel B). The ability of such recombinant proteins to in-
duce Axl receptor tyrosine phosphorylation in Cos cells was 
further assayed. Equal amounts of the respective chimeric 
constructs as assessed by Western blot were added to Cos 
cells for 10 min at 37°C. Analysis of receptor autophospho-
rylation was carried out as previously described [13]. Gas6 as 
well as Gas6SV were able to induce Axl receptor phosporyla-
tion. According to the previous results, only Gas6AC was 
able to activate Axl receptor, while Gas6AD and Gas6-
DPS, both lacking the D domain of Gas6, did not show 
activity (Fig. 3, panel B). These results therefore confirm the 
requirement of D domain for Axl receptor activation and 
show that this region is still able to activate the receptor 
when separated from the EGF repeats. Our evidence points 
to the potential role of the processing of GasoSV in regulating 
ligand availability (Fig. 4). Indeed the processed p50 product 
retains receptor stimulating activity but is no longer associ-
ated with the N-terminal p36 region. By analogy with the Gla 
domain of protein S and other vitamin K dependent proteins, 
the N-terminal region, containing the Gla domain of Gas6, 
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Fig. 3. Deletion mutant analysis of Gas6 domain involved in Axl activation. A: Scheme of human Gas6 and GasoSV domains organisation 
and position of human Gas6 deletions mutants (Gas6AC and Gas6AD) analysed by receptor autophosphorylation assay. The shaded area rep-
resent the four EGF like repeats (C domain) while grey boxes indicates the large C-terminal D domain. The darker shaded box indicates the D 
domain of human protein S that was inserted in Gas6 (Gas6-DPS). The blackened box is the 43 amino acid peptide of the GasoSV form. B: 
Western blot analysis of supernatant from COS-7 cells after transfection with the cDNAs described in A. Equal amounts of conditioned me-
dium were loaded on SDS-PAGE gels and analysed by Western blot using an antibody recognising N-terminal region of Gas6. A petri dish 
was mock transfected and used as control. C: Western blot analysis with antiphosphotyrosine antibodies of Axl receptors immunoprecipitated 
from COS-7 cells. Supernatants described in B were analysed for their ability to induce Axl receptor phosphorylation. The result shown here is 
representative of three separate experiments. 
has the potential to localise Gas6 to the membrane compart-
ment [17]. Thus Gas6 may be sequestered on the surface of 
cells at, or very near, the site of synthesis. Processing of the 
splice variant protein could therefore serve as a means of 
separating the receptor activating region from the region re-
sponsible for interaction to membranes, or potential ECM 
binding sites, thereby releasing it from this local environment. 
As a consequence the released D domain would become avail-
able for activating receptors at sites remote from that of syn-
thesis. Our findings are in agreement with a recent report 
suggesting that SHBG like repeats present on Gas6 D domain 
are responsible for its biological activity, while the N-terminus 
modulates its activity [18]. The expression of an alternatively 
spliced form that allows the release of the receptor activation 
region from the whole molecule may therefore represent an 
additional and novel mechanism of growth factor availability 
control. 
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